Literature DB >> 8904613

Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines.

C C Smith1, P M Bennett, H M Pearce, P I Harrison, D J Reynolds, J K Aronson, D G Grahame-Smith.   

Abstract

1. We have retrospectively analysed data collected by a local adverse drug reactions reporting scheme in an acute hospital medical setting and have determined the numbers and types of reactions that would have merited notification as yellow card reports according to the guidelines of the Committee on Safety of Medicines. 2. The data related to 20,695 consecutive acute general medical admissions on seven general medical wards (140 beds) and were collected over 3 years, from April 1990 to March 1993. 3. Over 3 years there were 1420 reports of suspected adverse drug reactions, a rate of 68.7 per 1000 admissions. 4. If the guidelines for reporting issued by the Committee on Safety of Medicines had been strictly followed, 477 yellow cards would have been sent (23.1 per 1000 admissions). In 357 of these reports (74.8%), the reaction had caused admission to hospital. Only 31 of the 477 potential cards (6.5%) involved black triangle drugs and 10 of these were for minor reactions. 5. Only 30 of the 477 potential yellow cards (6.3%) were known to have been sent. The majority of those reactions not reported were for drug-related admissions, most of which were for well-known reactions to established drugs. 6. We have confirmed and quantified the extent of under-reporting of serious suspected adverse drug reactions to the Committee on Safety of Medicines from our hospital medical unit.

Mesh:

Year:  1996        PMID: 8904613      PMCID: PMC2042689          DOI: 10.1046/j.1365-2125.1996.04376.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  63 in total

1.  Is reporting rate a good predictor of risks associated with drugs?

Authors:  C Pierfitte; B Bégaud; R Lagnaoui; N D Moore
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

2.  Computerized survelliance of adverse drug reactions in hospital: pilot study.

Authors:  T Azaz-Livshits; M Levy; B Sadan; M Shalit; G Geisslinger; K Brune
Journal:  Br J Clin Pharmacol       Date:  1998-03       Impact factor: 4.335

3.  First results from an intensified monitoring system to estimate drug related hospital admissions.

Authors:  S Schneeweiss; M Göttler; J Hasford; W Swoboda; M Hippius; A K Hoffmann; A K Riethling; J Krappweis
Journal:  Br J Clin Pharmacol       Date:  2001-08       Impact factor: 4.335

Review 4.  What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world.

Authors:  Rohini B M Fernandopulle; Krisantha Weerasuriya
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

5.  Nurse prescribers & reporters.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

6.  Workshop- and telephone-based interventions to improve adverse drug reaction reporting: a cluster-randomized trial in Portugal.

Authors:  Maria Teresa Herdeiro; Inês Ribeiro-Vaz; Mónica Ferreira; Jorge Polónia; Amílcar Falcão; Adolfo Figueiras
Journal:  Drug Saf       Date:  2012-08-01       Impact factor: 5.606

7.  Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database.

Authors:  Patrick Waller; Mary Shaw; Davidson Ho; Saad Shakir; Shah Ebrahim
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

8.  Write on.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

9.  A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone.

Authors:  Yoon K Loke; Sheena Derry; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

Review 10.  Drug-related problems in hospitals: a review of the recent literature.

Authors:  Anita Krähenbühl-Melcher; Raymond Schlienger; Markus Lampert; Manuel Haschke; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.